Today: 7 February 2026
Subscribe
Browse Category

NYSE:HIMS News 3 November 2025 - 6 February 2026

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers Health shares fell 2.6% to $22.88 Friday after launching a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill. Novo called the move “illegal mass compounding” and threatened legal action, while the FDA warned it would act against unapproved copycat drugs. Hims said its pill uses “liposomal technology” to aid absorption but gave no details. Nearly a third of Hims shares are out on loan for short bets.
6 February 2026
·
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NEW YORK, December 31, 2025, 05:39 ET — Premarket Shares of Hims & Hers Health Inc (HIMS) fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google The drift lower keeps attention on the telehealth group’s exposure to the fast-moving market for GLP-1 weight-loss drugs — a category that has become a major battleground for pricing, access and consumer demand. That matters now because GLP-1 drugs, a class of diabetes and obesity medicines that reduce appetite, are
31 December 2025
····
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar

NEW YORK, December 29, 2025, 01:59 ET — Market closed. Hims & Hers Health Inc shares last closed down about 1% at $34.31 on Friday, extending a four-session slide as U.S. markets headed into the final trading days of the year. Investing.com The move matters now because year-end trading typically brings lighter volumes and sharper swings, leaving growth stocks sensitive to shifts in rate expectations and risk appetite. Investopedia For Hims & Hers, investors have also been parsing how quickly the telehealth company can scale its physical operations as it pushes deeper into higher-touch care that relies on pharmacy and
29 December 2025
·
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims & Hers Health (NYSE: HIMS) is back in the spotlight after a new $250 million buyback, expansion into Canada, and fresh acquisitions in lab testing and blood diagnostics. Here’s a comprehensive look at HIMS stock price, latest news, GLP‑1 risks, and Wall Street forecasts as of December 6, 2025. Hims Stock Today: Price, Valuation and Volatility As of the close on Friday, December 5, 2025, Hims & Hers Health (NYSE: HIMS) finished trading at around $39–39.3 per share, giving the telehealth company a market capitalization of roughly $8.9–9.0 billion. MarketBeat+2CoinCodex+2 Over the last 12 months, HIMS has traded between
6 December 2025
·
Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers Health, Inc. (NYSE: HIMS) is back in the spotlight. In Thursday’s session on December 4, 2025, the telehealth stock climbed roughly 5–8%, trading around $40 and valuing the company at about $12.8 billion, after a flurry of strategic announcements. Finviz+1 The immediate catalysts: At the same time, fresh coverage from MarketBeat, TipRanks, Zacks and others is revisiting the stock’s valuation, short interest and earnings trajectory. MarketBeat+3MarketBeat+3TipRanks+3 Below is a detailed, news‑driven look at HIMS stock as of December 4, 2025 – including today’s headlines, the latest financials, analyst forecasts, and the key bull and bear arguments. HIMS
4 December 2025
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the daystockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers (more on that below), signaling renewed investor optimism. Even after recent volatility, HIMS stock has had a stellar year. At ~$44–$47, shares remain
4 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertaintysimplywall.st. Key analysts (TD Cowen, KeyBanc) maintain
3 November 2025
···

Stock Market Today

CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

7 February 2026
CleanSpark shares jumped 22% to $10.08 Friday after quarterly results and an AI infrastructure update, following bitcoin’s rebound above $70,000. The company reported a quarterly net loss tied to bitcoin price swings and outlined plans to expand power capacity in Houston. Peers Marathon Digital and Riot Platforms also surged. Upcoming U.S. jobs and inflation data next week could add further volatility.
Go toTop